John C. Whitin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
John C. Whitin has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Harvey J. Cohen
Department of Pediatrics, University of Rochester Medical Center, Strong Memorial Hospital, Rochester
4 shared publications - Harvey J. Cohen
Affiliation: Department of Pediatrics, Stanford University, Stanford, California, United States of America
4 shared publications - James Palis
Department of Pediatrics, University of Rochester Medical Center, Rochester, NY
2 shared publications - Paul D. Kingsley
Department of Pediatrics
2 shared publications - Tom Ts Yu
Department of Pediatrics, Stanford University, Stanford, CA 94305, USA
2 shared publications - Xuefeng Bruce Ling
School of Medicine, Stanford University
2 shared publications
Latest Publications
- Open Access
Quantitative LCMS for ceramides/dihydroceramides: pregnancy baseline biomarkers and potential metabolic messengers
Ceramides and dihydroceramides are sphingolipids that present in abundance at the cellular membrane of eukaryotes. Although their metabolic dysregulation has been implicated in many diseases, our knowledge about circulating ceramide changes during the pregnancy remains limited. In this study, we present the development and validation of a high-throughput liquid chromatography-tandem mass spectrometric (LC/MS/MS) method for simultaneous quantification of 16 ceramides and 10 dihydroceramides in human serum within 5 mins by using stable isotope-labeled ceramides as internal standards (ISs). This method employs a protein precipitation method for high throughput sample preparation, reverse phase isocratic elusion for chromatographic separation, and Multiple Reaction Monitoring (MRM) for mass spectrometric detection. To qualify for clinical applications, our assay was validated against the FDA guidelines: the Lower Limit of Quantitation (LLOQ as low as 1 nM), linearity (R 2 >0.99), precision (Coefficient of Variation85%), and carryover (<0.1%). With enhanced sensitivity and specificity from this method, we have, for the first time, determined the serological levels of ceramides and dihydroceramides to reveal unique temporal gestational patterns. Our approach could have value in providing insights into disorders of pregnancy.
Open AccessQuantitative LCMS for ceramides/dihydroceramides: pregnancy baseline biomarkers and potential metabolic messengers
Ceramides and dihydroceramides are sphingolipids that present in abundance at the cellular membrane of eukaryotes. Although their metabolic dysregulation has been implicated in many diseases, our knowledge about circulating ceramide changes during the pregnancy remains limited. In this study, we present the development and validation of a high-throughput liquid chromatography-tandem mass spectrometric (LC/MS/MS) method for simultaneous quantification of 16 ceramides and 10 dihydroceramides in human serum within 5 mins by using stable isotope-labeled ceramides as internal standards (ISs). This method employs a protein precipitation method for high throughput sample preparation, reverse phase isocratic elusion for chromatographic separation, and Multiple Reaction Monitoring (MRM) for mass spectrometric detection. To qualify for clinical applications, our assay was validated against the FDA guidelines: the Lower Limit of Quantitation (LLOQ as low as 1 nM), linearity (R 2 >0.99), precision (Coefficient of Variation85%), and carryover (<0.1%). With enhanced sensitivity and specificity from this method, we have, for the first time, determined the serological levels of ceramides and dihydroceramides to reveal unique temporal gestational patterns. Our approach could have value in providing insights into disorders of pregnancy.
- Open Access
- 8 September 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 358
Identifying technical aliases in SELDI mass spectra of complex mixtures of proteins
Biomarker discovery datasets created using mass spectrum protein profiling of complex mixtures of proteins contain many peaks that represent the same protein with different charge states. Correlated variables such as these can confound the statistical analyses of proteomic data. Previously we developed an algorithm that clustered mass spectrum peaks that were biologically or technically correlated. Here we demonstrate an algorithm that clusters correlated technical aliases only.
- 8 September 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 358
Open AccessIdentifying technical aliases in SELDI mass spectra of complex mixtures of proteins
Biomarker discovery datasets created using mass spectrum protein profiling of complex mixtures of proteins contain many peaks that represent the same protein with different charge states. Correlated variables such as these can confound the statistical analyses of proteomic data. Previously we developed an algorithm that clustered mass spectrum peaks that were biologically or technically correlated. Here we demonstrate an algorithm that clusters correlated technical aliases only.
- Open Access
- 6 December 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 130
A diagnostic algorithm combining clinical and molecular data distinguishes Kawasaki disease from other febrile illnesses
Background: Kawasaki disease is an acute vasculitis of infants and young children that is recognized through a constellation of clinical signs that can mimic other benign conditions of childhood. The etiology remains unknown and there is no specific laboratory-based test to identify patients with Kawasaki disease. Treatment to prevent the complication of coronary artery aneurysms is most effective if administered early in the course of the illness. We sought to develop a diagnostic algorithm to help clinicians distinguish Kawasaki disease patients from febrile controls to allow timely initiation of treatment.Methods: Urine peptidome profiling and whole blood cell type-specific gene expression analyses were integrated with clinical multivariate analysis to improve differentiation of Kawasaki disease subjects from febrile controls.Results: Comparative analyses of multidimensional protein identification using 23 pooled Kawasaki disease and 23 pooled febrile control urine peptide samples revealed 139 candidate markers, of which 13 were confirmed (area under the receiver operating characteristic curve (ROC AUC 0.919)) in an independent cohort of 30 Kawasaki disease and 30 febrile control urine peptidomes. Cell type-specific analysis of microarrays (csSAM) on 26 Kawasaki disease and 13 febrile control whole blood samples revealed a 32-lymphocyte-specific-gene panel (ROC AUC 0.969). The integration of the urine/blood based biomarker panels and a multivariate analysis of 7 clinical parameters (ROC AUC 0.803) effectively stratified 441 Kawasaki disease and 342 febrile control subjects to diagnose Kawasaki disease.Conclusions: A hybrid approach using a multi-step diagnostic algorithm integrating both clinical and molecular findings was successful in differentiating children with acute Kawasaki disease from febrile controls.
- 6 December 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 130
Open AccessA diagnostic algorithm combining clinical and molecular data distinguishes Kawasaki disease from other febrile illnesses
Background: Kawasaki disease is an acute vasculitis of infants and young children that is recognized through a constellation of clinical signs that can mimic other benign conditions of childhood. The etiology remains unknown and there is no specific laboratory-based test to identify patients with Kawasaki disease. Treatment to prevent the complication of coronary artery aneurysms is most effective if administered early in the course of the illness. We sought to develop a diagnostic algorithm to help clinicians distinguish Kawasaki disease patients from febrile controls to allow timely initiation of treatment.Methods: Urine peptidome profiling and whole blood cell type-specific gene expression analyses were integrated with clinical multivariate analysis to improve differentiation of Kawasaki disease subjects from febrile controls.Results: Comparative analyses of multidimensional protein identification using 23 pooled Kawasaki disease and 23 pooled febrile control urine peptide samples revealed 139 candidate markers, of which 13 were confirmed (area under the receiver operating characteristic curve (ROC AUC 0.919)) in an independent cohort of 30 Kawasaki disease and 30 febrile control urine peptidomes. Cell type-specific analysis of microarrays (csSAM) on 26 Kawasaki disease and 13 febrile control whole blood samples revealed a 32-lymphocyte-specific-gene panel (ROC AUC 0.969). The integration of the urine/blood based biomarker panels and a multivariate analysis of 7 clinical parameters (ROC AUC 0.803) effectively stratified 441 Kawasaki disease and 342 febrile control subjects to diagnose Kawasaki disease.Conclusions: A hybrid approach using a multi-step diagnostic algorithm integrating both clinical and molecular findings was successful in differentiating children with acute Kawasaki disease from febrile controls.
- 5 December 2011
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 38 (1) , 89-96
Identification of protein marker in vaginal wall tissues of women with stress urinary incontinence by protein chip array
Aim: We sought to investigate protein biomarkers for stress urinary incontinence (SUI) in vaginal tissues using surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry (SELDI‐TOF MS) and examine if this is a reliable methodology to examine proteins in small tissue specimens. Material and Methods: We compared protein expression profile of vaginal tissue from women with SUI and continent controls. A 22.6 kDa peak was identified by subsequent weak cation‐exchange, reverse‐phase fractionation, gel electrophoresis, and trypsin digestion, then analyzed by matrix assisted laser desorption/ionization mass spectrometry (MALDI MS) and MALDI MS‐MS. Biomarker identity and expression level were confirmed by Western‐blotting and immunohistochemistry. Results: Expression of the 22.6 kDa protein, identified as SM‐22α, was significantly higher in women with SUI versus controls. A 3 × 3‐mm tissue sample was sufficient for identification. Western‐blot/immunohistochemistry confirmed the SELDI‐TOS MS findings. Conclusion: SM‐22α, a marker for myofibroblasts, was identified as a biomarker of SUI. Differential protein profiling by SELDI‐TOF MS is a powerful and reliable tool for urogynecological research as it allows us to study an array of proteins simultaneously using small tissue samples.
- 5 December 2011
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 38 (1) , 89-96
Identification of protein marker in vaginal wall tissues of women with stress urinary incontinence by protein chip array
Aim: We sought to investigate protein biomarkers for stress urinary incontinence (SUI) in vaginal tissues using surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry (SELDI‐TOF MS) and examine if this is a reliable methodology to examine proteins in small tissue specimens. Material and Methods: We compared protein expression profile of vaginal tissue from women with SUI and continent controls. A 22.6 kDa peak was identified by subsequent weak cation‐exchange, reverse‐phase fractionation, gel electrophoresis, and trypsin digestion, then analyzed by matrix assisted laser desorption/ionization mass spectrometry (MALDI MS) and MALDI MS‐MS. Biomarker identity and expression level were confirmed by Western‐blotting and immunohistochemistry. Results: Expression of the 22.6 kDa protein, identified as SM‐22α, was significantly higher in women with SUI versus controls. A 3 × 3‐mm tissue sample was sufficient for identification. Western‐blot/immunohistochemistry confirmed the SELDI‐TOS MS findings. Conclusion: SM‐22α, a marker for myofibroblasts, was identified as a biomarker of SUI. Differential protein profiling by SELDI‐TOF MS is a powerful and reliable tool for urogynecological research as it allows us to study an array of proteins simultaneously using small tissue samples.
- 1 July 2002
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 283 (1) , F20-F28
Extracellular glutathione peroxidase is secreted basolaterally by human renal proximal tubule cells
Extracellular glutathione peroxidase (eGPx) is a secreted selenoenzyme with GPx activity. eGPx protein and activity are found in blood plasma and other extracellular fluids. eGPx in plasma is predominantly derived from the proximal tubules of kidneys in humans. Two types of human proximal tubule cells were cultured on semipermeable polycarbonate membranes to determine whether these cells secrete eGPx in a polarized direction. Immortalized human proximal tubule HK-2 cells and primary human proximal tubule cells formed confluent monolayers when cultured on these membrane inserts in culture dishes, as evidenced by transepithelial resistance. Both cell lines also constituted a barrier to diffusion of a fluoresceinated dextran of 75 kDa, a size similar to eGPx homotetramers. In both cell lines, 6- to 12-fold more35S-methionine-labeled eGPx was immunoprecipitated from the basolateral media than from the apical media, indicating basolateral secretion of eGPx. eGPx was immunolocalized to the extracellular fluid at the basolateral surface of proximal tubules in human kidney. These data support the conclusion that eGPx is secreted through the basolateral membrane of human kidney proximal tubule cells into the extracellular fluid of the kidney, and from there enters blood plasma.
- 1 July 2002
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 283 (1) , F20-F28
Extracellular glutathione peroxidase is secreted basolaterally by human renal proximal tubule cells
Extracellular glutathione peroxidase (eGPx) is a secreted selenoenzyme with GPx activity. eGPx protein and activity are found in blood plasma and other extracellular fluids. eGPx in plasma is predominantly derived from the proximal tubules of kidneys in humans. Two types of human proximal tubule cells were cultured on semipermeable polycarbonate membranes to determine whether these cells secrete eGPx in a polarized direction. Immortalized human proximal tubule HK-2 cells and primary human proximal tubule cells formed confluent monolayers when cultured on these membrane inserts in culture dishes, as evidenced by transepithelial resistance. Both cell lines also constituted a barrier to diffusion of a fluoresceinated dextran of 75 kDa, a size similar to eGPx homotetramers. In both cell lines, 6- to 12-fold more35S-methionine-labeled eGPx was immunoprecipitated from the basolateral media than from the apical media, indicating basolateral secretion of eGPx. eGPx was immunolocalized to the extracellular fluid at the basolateral surface of proximal tubules in human kidney. These data support the conclusion that eGPx is secreted through the basolateral membrane of human kidney proximal tubule cells into the extracellular fluid of the kidney, and from there enters blood plasma.
- 1 April 1996
- Published by Springer Nature in Pediatric Research
- Vol. 39 (4) , 372
PLASMA GLUTATHIONE PEROXIDASE AND ITS RELATIONSHIP TO RENAL PROXIMAL TUBULE FUNCTION. • 2215
- 1 April 1996
- Published by Springer Nature in Pediatric Research
- Vol. 39 (4) , 372
PLASMA GLUTATHIONE PEROXIDASE AND ITS RELATIONSHIP TO RENAL PROXIMAL TUBULE FUNCTION. • 2215
- 1 April 1987
- Published by Springer Nature in Pediatric Research
- Vol. 21 (4) , 297A
HUMAN NEUTROPHIL (PMN) INTERACTIONS WITH HUMAN IMMUNE COMPLEXES (IC)
- 1 April 1987
- Published by Springer Nature in Pediatric Research
- Vol. 21 (4) , 297A
HUMAN NEUTROPHIL (PMN) INTERACTIONS WITH HUMAN IMMUNE COMPLEXES (IC)
- 1 April 1987
- Published by Springer Nature in Pediatric Research
- Vol. 21 (4) , 296A
MEASUREMENT OF L-ASPARAGINE (ASN) LEVELS IN THE PRESENCE OF E. COLI L-ASPARAGINASE (ASNASE) IS IMPROVED BY THE USE OF ASPARTIC β SEMIALDEHYDE (ASA)
- 1 April 1987
- Published by Springer Nature in Pediatric Research
- Vol. 21 (4) , 296A
MEASUREMENT OF L-ASPARAGINE (ASN) LEVELS IN THE PRESENCE OF E. COLI L-ASPARAGINASE (ASNASE) IS IMPROVED BY THE USE OF ASPARTIC β SEMIALDEHYDE (ASA)